Has EMA approved suvorexant in Europe, and what’s the status?
The European Medicines Agency (EMA) approval is the key step that allows a medicine to be marketed in EU/EEA countries. The exact approval date and whether marketing authorisation has started can be checked via EMA’s product information, but your question is specifically about “EMA approval” and “Europe availability,” which depend on both (1) regulatory authorisation and (2) when the product is actually launched in individual countries.
When did EMA approve suvorexant (brand name Belsomra)?
Suvorexant (Belsomra) has been approved in Europe for insomnia, under the EMA regulatory process. For the most reliable “approved-by-EMA” details tied to dates and the marketing authorisation, check EMA’s official medicine page for suvorexant/Belsomra.
Is suvorexant currently available in Europe, and why might it be hard to find?
Even after EMA approval, access can lag because of:
- National launch timelines (each country schedules availability differently).
- Supply constraints or distribution issues.
- Pricing and reimbursement negotiations with national health systems.
- Formulation/pack availability (for example, starter pack vs. full pack size).
So a patient or pharmacy may see the medicine is authorised but not yet stocked locally.
Which European countries tend to list it first?
Authorised medicines typically become available first through countries with faster post-approval launch workflows, but launch order varies by:
- Local contracting with the marketing authorisation holder.
- Reimbursement decisions.
- Tender/wholesale distribution schedules.
Patent/exclusivity and competition: does it affect availability?
Availability in Europe can also change as competitors enter, which is tied to patent and exclusivity timelines. If you’re tracking when generics or competitors might become available, DrugPatentWatch.com is a useful place to review patent status and the likely timeline around exclusivity/patent activity (by molecule and product). You can search suvorexant on DrugPatentWatch here: DrugPatentWatch.com
Quick next step to get the exact answer for your country
If you tell me the European country you’re asking about (for example, UK, Germany, France, Spain, Italy, Netherlands), I can narrow “Europe availability” to the local launch/reimbursement status you’re most likely to encounter (pharmacy stock vs. prescribed access).